235 results on '"Gomez-Reino, Juan J"'
Search Results
2. Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs
3. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis
4. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
5. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
6. Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain
7. New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history
8. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis
9. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
10. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis
11. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes
12. Predictors of treatment failure and mortality in native septic arthritis
13. Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review
14. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
15. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
16. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
17. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience
18. THERAPY: The NICE position on indications for biologics and biosimilars
19. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
20. Adipokines as novel modulators of lipid metabolism
21. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
22. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
23. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
24. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis
25. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
26. Chapter 9 - Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
27. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective
28. Reply
29. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
30. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
31. Association of anti–citrullinated vimentin and anti–citrullinated α-enolase antibodies with subsets of rheumatoid arthritis
32. Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
33. Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis
34. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
35. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
36. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
37. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors
38. Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations
39. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
40. A broad analysis of IL1 polymorphism and rheumatoid arthritis
41. Association of Interferon Regulatory Factor 5 Haplotypes, Similar to That Found in Systemic Lupus Erythematosus, in a Large Subgroup of Patients With Rheumatoid Arthritis
42. Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis
43. Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes
44. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage
45. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
46. Polymorphism of the Interleukin-1 Receptor Antagonist Gene: A Factor in Susceptibility to Rheumatoid Arthritis in a Spanish Population
47. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor
48. Association of PDCD1 With Susceptibility to Systemic Lupus Erythematosus: Evidence of Population-Specific Effects
49. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus
50. Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice-Pooled Data from the Eurospa Research Network Collaboration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.